COMPANY

Trethera

HQ: Sherman Oaks, CA source · trethera.com ↗ · West Coast

Location: Sherman Oaks, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: acute disseminated encephalomyelitis systemic lupus erythematosus optic neuritis Oncology crohn's disease TRE-515

1Trials (company is sponsor)10NIH grants

Funding and NIH signals

NIH award NIH awarded $897K (STTR Phase II 5R42DK138578-03, continuation, notice Sep 17, 2026); 3 NIH awards totaling $3.04M in the last 12 months. NIH RePORTER 5R42DK138578-03 (Sep 17, 2026)
Evidence (3 events)
- Sep 17, 2026 · NIH RePORTER 5R42DK138578-03
  Organization: TRETHERA CORPORATION; City/State: SHERMAN OAKS, CA; Project number: 5R42DK138578-03; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 897265; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease; Organization type: Domestic For-Profits
- Aug 11, 2026 · NIH RePORTER 5R44AI188587-02
  Organization: TRETHERA CORPORATION; City/State: SHERMAN OAKS, CA; Project number: 5R44AI188587-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 994978; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus; Organization type: Domestic For-Profits
- Aug 5, 2026 · NIH RePORTER 5R44CA302066-02
  Organization: TRETHERA CORPORATION; City/State: SHERMAN OAKS, CA; Project number: 5R44CA302066-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-05; FY total cost (award amount): 1150000; Administering IC: National Cancer Institute; Project title: Development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway through combinatorial murine studies to enable further clinical advancement in prostate tumors; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 17, 2026 Grant Government grant — STTR: $897,265 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Aug 11, 2026 Grant Government grant — SBIR: $994,978 (annual award, as published), announced Aug 11, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 5, 2026 Grant Government grant — SBIR: $1.15M (annual award, as published), announced Aug 5, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Mar 31, 2026 Partnership Partnership / licensing announced Mar 31, 2026. Source: company's own press page. source ↗
Dec 16, 2025 Grant Government grant: $2.7M (total, as published), announced Dec 16, 2025. Source: company's own press page. source ↗
Sep 23, 2025 Grant Government grant: $1.8M (total, as published), announced Sep 23, 2025. Source: company's own press page. source ↗
Sep 5, 2025 Grant Government grant — SBIR: $406,500 (annual award, as published), announced Sep 5, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Sep 2, 2025 Grant Government grant — STTR: $905,290 (annual award, as published), announced Sep 2, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
Aug 26, 2025 Grant Government grant: $2.3M (total, as published), announced Aug 26, 2025. Source: company's own press page. source ↗
Aug 19, 2025 Grant Government grant: $3M (total, as published), announced Aug 19, 2025. Source: company's own press page. source ↗
Aug 18, 2025 Grant Government grant — SBIR: $1.15M (annual award, as published), announced Aug 18, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Aug 7, 2025 Grant Government grant — SBIR: $994,978 (annual award, as published), announced Aug 7, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 15, 2025 Grant Government grant — SBIR: $1M (annual award, as published), announced Jul 15, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jun 3, 2025 Partnership Partnership / licensing announced Jun 3, 2025. Source: company's own press page. source ↗
Feb 14, 2025 Grant Government grant — STTR: $622,448 (annual award, as published), announced Feb 14, 2025. Agency: NIH/NEI. Source: government award database. source ↗
Sep 23, 2021 Trial start Phase 1: Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors source ↗

Upcoming milestones

Dec 31, 2026 (ESTIMATED) · Phase 1 · Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors · NCT05055609

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Mar 31, 2026 Partnership / licensing announced Mar 31, 2026. Source: company's own press page. source ↗
Jun 3, 2025 Partnership / licensing announced Jun 3, 2025. Source: company's own press page. source ↗
Sep 17, 2026 Government grant — STTR: $897,265 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIDDK. Source: government award database. source ↗
Aug 11, 2026 Government grant — SBIR: $994,978 (annual award, as published), announced Aug 11, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 5, 2026 Government grant — SBIR: $1.15M (annual award, as published), announced Aug 5, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Dec 16, 2025 Government grant: $2.7M (total, as published), announced Dec 16, 2025. Source: company's own press page. source ↗
Sep 23, 2025 Government grant: $1.8M (total, as published), announced Sep 23, 2025. Source: company's own press page. source ↗
Sep 5, 2025 Government grant — SBIR: $406,500 (annual award, as published), announced Sep 5, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Sep 2, 2025 Government grant — STTR: $905,290 (annual award, as published), announced Sep 2, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
Aug 26, 2025 Government grant: $2.3M (total, as published), announced Aug 26, 2025. Source: company's own press page. source ↗
Aug 19, 2025 Government grant: $3M (total, as published), announced Aug 19, 2025. Source: company's own press page. source ↗
Aug 18, 2025 Government grant — SBIR: $1.15M (annual award, as published), announced Aug 18, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Aug 7, 2025 Government grant — SBIR: $994,978 (annual award, as published), announced Aug 7, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 15, 2025 Government grant — SBIR: $1M (annual award, as published), announced Jul 15, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Feb 14, 2025 Government grant — STTR: $622,448 (annual award, as published), announced Feb 14, 2025. Agency: NIH/NEI. Source: government award database. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT05055609	Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors	Phase 1	Recruiting	Sep 23, 2021	Dec 31, 2026 (estimated)

NIH awards 10

Annual award amounts. Total $5.7M.

Jul 5, 2024 NIH award 5R41AI179191-02 FY2024: $297,146 awarded for that fiscal year; activity R41 (STTR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a Novel, Targeted Small source ↗
Jul 2, 2024 NIH award 1R44AI186534-01 FY2024: $1,050,000 awarded for that fiscal year; activity R44 (SBIR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a novel, targeted smal source ↗
May 22, 2024 NIH award 5R44CA281485-02 FY2024: $696,570 awarded for that fiscal year; activity R44 (SBIR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a Novel, Targeted Small source ↗
May 14, 2024 NIH award 5R41AI179213-02 FY2024: $305,715 awarded for that fiscal year; activity R41 (STTR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a Novel, Targeted Small source ↗
Feb 8, 2024 NIH award 4R42EY034397-02 FY2024: $615,858 awarded for that fiscal year; activity R42 (STTR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a Novel, Targeted Small source ↗
Sep 19, 2023 NIH award 1R41DK138578-01 FY2023: $395,119 awarded for that fiscal year; activity R41 (STTR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a Novel, Targeted Small source ↗
Jul 31, 2023 NIH award 1R41AI179191-01 FY2023: $304,461 awarded for that fiscal year; activity R41 (STTR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a Novel, Targeted Small source ↗
Jun 21, 2023 NIH award 1R41AI179213-01 FY2023: $305,135 awarded for that fiscal year; activity R41 (STTR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a Novel, Targeted Small source ↗
May 30, 2023 NIH award 1R44CA281485-01 FY2023: $1,349,805 awarded for that fiscal year; activity R44 (SBIR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a Novel, Targeted Smal source ↗
Sep 15, 2022 NIH award 1R42EY034397-01 FY2022: $368,195 awarded for that fiscal year; activity R42 (STTR); PI SCHULTZ, KENNETH; recipient as written: TRETHERA CORPORATION, SHERMAN OAKS, CA. Development of a Novel, Targeted Small source ↗